| Mobidiag–Hologic: investment, 202104– acquisition €600m in cash ANNOUNCED |
2021-04-08 |
| Step Pharma–Hadean Ventures: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Hadean Ventures |
2021-03-24 |
| Step Pharma–SEVERAL: investment, 202103 financing round Series B €35m co-led by new investors Hadean Ventures + Sunstone Life Science Ventures |
2021-03-24 |
| Step Pharma–Sunstone Life Science: investment, 202103 financing round Series B totalling €35m incl new + co-lead investor Sunstone Life Science |
2021-03-24 |
| Aura Biosciences–SEVERAL: investment, 202103 financing round $80m led by Matrix Capital Management + Surveyor Capital |
2021-03-22 |
| Cellink–SEVERAL: credit, 202103–202603 convertible bonds SEK1.5b at 2.875%pa convertible into B Class shares at SEK598.5/share |
2021-03-12 |
| Cellink–SEVERAL: investment, 202103 capital increase SEK1.5b directed issue of new Class B Shares at SEK420/share |
2021-03-12 |
| MatTek–Cellink: investment, 202103– acquisition $68m net of cash/debt with $54.4m in cash + $13.6m in shares ANNOUNCED |
2021-03-10 |
| BioPhero–DCVC: investment, 202103 financing round Series A totalling $17m incl new + lead investor DCVC Bio |
2021-03-09 |
| BioPhero–FMC: investment, 202103 financing round Series A totalling $17m incl new + co-investor FMC Ventures |
2021-03-09 |
| BioPhero–Novo Group: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Novo Holdings |
2021-03-09 |
| BioPhero–SEVERAL: investment, 202103 financing round Series A $17m led by DCVC Bio with FMC Ventures + Syngenta Ventures + Novo Holdings |
2021-03-09 |
| BioPhero–Syngenta: investment, 202103 financing round Series A totalling $17m incl existing + co-investor Syngenta Ventures |
2021-03-09 |
| Exscientia–BlackRock: investment, 202103 financing round Series C extension totalling $40m + closing at total of $100m incl new investor BlockRock |
2021-03-04 |
| Exscientia–SEVERAL: investment, 202103 financing round Series C extension $40m + closing at total of $100m with BlockRock joining existing investors |
2021-03-04 |
| Oxular–NeoMed: investment, 202103 financing round totalling £27m incl existing + co-investor NeoMed |
2021-03-01 |
| Oxular–SEVERAL: investment, 202103 financing round £27m led by Forbion |
2021-03-01 |
| Oxular–V-Bio Ventures: investment, 202103 financing round totalling £27m incl existing + co-investor V-Bio Ventures |
2021-03-01 |
| Tetramer Shop–10x Genomics: investment, 202102 acquisition €na of Tetramer Shop ApS by 10x Genomics Inc |
2021-02-24 |
| Altasciences–Novo Group: investment, 202102– acquisition of Altasciences by Novo Holdings from Audax Private Equity ANNOUNCED |
2021-02-22 |
| Almirall–MC2 Therapeutics: Wynzora Cream, 202102– license excl to commercialise Wynzora Cream for plaque psoriasis in Europe for Almirall |
2021-02-17 |
| Cognate BioServices–Charles River: investment, 202102– acquisition $875m in cash by Charles River ANNOUNCED |
2021-02-17 |
| Ginolis–Cellink: investment, 202102–202103 acquisition 100% of Ginolis debt/cash-free for €65.7m with €41.6m in cash + €24.1m in shares |
2021-02-15 |
| EnginZyme–SEB: investment, 202102 financing round Series A extension totalling €4.6m incl new + co-investor SEB Greentech VC |
2021-02-11 |
| EnginZyme–SEVERAL: investment, 202102 financing round Series A extension €4.6m led by Industrifonden + incl SEB Greentech VC + existing shareholders |
2021-02-11 |
| EnginZyme–Sweden (govt): investment, 202102 financing round Series A extension totalling €4.6m incl new + lead investor Industrifonden |
2021-02-11 |
| Evaxion Biotech–LifeSci: public relations, 202102 supply service existent by LifeSci Advisors LLC |
2021-02-10 |
| Evaxion Biotech–SEVERAL: investment, 202102 US IPO $30m+$4.5m with 3m+450k ADSs at $10/ADS at Nasdaq Capital Market |
2021-02-10 |
| IO Biotech–Avoro Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Avoro Capital |
2021-01-13 |
| IO Biotech–Eurazeo: investment, 202101 financing round Series B totalling €127m incl new + co-investor Idinvest Partners |
2021-01-13 |
| IO Biotech–HBM: investment, 202101 financing round Series B totalling €127m incl new + lead investor HBM Healthcare Investments |
2021-01-13 |
| IO Biotech–Kurma: investment, 202101 financing round Series B totalling €127m incl new + co-investor Kurma Partners |
2021-01-13 |
| IO Biotech–Lundbeck: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Lundbeckfonden Emerge |
2021-01-13 |
| IO Biotech–Novo Group: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Novo Seeds |
2021-01-13 |
| IO Biotech–PFM Health Sciences: investment, 202101 financing round Series B totalling €127m incl new + co-investor PFM Health Sciences |
2021-01-13 |
| IO Biotech–RA Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor RA Capital Management |
2021-01-13 |
| IO Biotech–Samsara BioCapital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Samsare BioCapital |
2021-01-13 |
| IO Biotech–Serrado Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Serrada Capital |
2021-01-13 |
| IO Biotech–SEVERAL: investment, 202101 financing round Series B €127m led by new investor HBM Healthcare Investments |
2021-01-13 |
| IO Biotech–Soleus Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Soleus Capital |
2021-01-13 |
| IO Biotech–Sunstone Life Science: investment, 202101 financing round Series B totalling €127m incl existing+ co-investor Sunstone Life Science |
2021-01-13 |
| IO Biotech–Vivo Capital: investment, 202101 financing round Series B totalling €127m incl new + co-investor Vivo Capital |
2021-01-13 |
| BioGeneration Ventures–Industriens Pension: investment, 202101 final closing of BGV IV totalling €140m incl investor Industriens Pension |
2021-01-07 |
| BioGeneration Ventures–Novo Group: investment, 202101 final closing of BGV IV totalling €140m incl investor Novo Ventures |
2021-01-07 |
| BioGeneration Ventures–SEVERAL: investment, 202101 final closing of BGV IV with €140m incl Lilly + Novo Ventures + BMS + Schroder Adveq et al |
2021-01-07 |
| CorWave–Novo Group: investment, 202101 financing round Series C totalling €35m incl existing + co-investor Novo Holdings |
2021-01-06 |
| CorWave–SEVERAL: investment, 202101 financing round Series C €35m led by new investor EIC Fund |
2021-01-06 |
| Faron Pharmaceuticals–Precision Medicine Group: public relations, 202101 service existent IR by Stern IR |
2021-01-04 |
| Immunicum–Van Herk: investment, 202012c largest shareholder holding 43% after merger of Immunicum with DCprime |
2020-12-31 |
| Hemab–Genmab: antibody technology, 202012 existent license to DuoBody platform to develop antibodies for bleeding disorders |
2020-12-14 |
| Hemab–Novo Group: antibody technology, 202012 existent license to IP to develop antibodies for bleeding disorders from Novo Nordisk AS |
2020-12-14 |
| Hemab–Novo Group: investment, 202012 seed investor Novo Seeds |
2020-12-14 |
| Evaxion Biotech–EU (govt): credit, 202012– EIB loan €20m under InnovFin program to advance AI-based vaccine research |
2020-12-09 |
| BioInnovation Institute–Novo Group: grant, 202012–203012 up to €470m funding over ten years to BBI from Novo Nordisk Foundation |
2020-12-08 |
| Single Technologies–SEVERAL: investment, 202012 financing round €5m oversubscribed share issue with existing + new investors |
2020-12-04 |
| Enduro Genetics–BioInnovation Institute: credit, 202012 pre-seed loan €470k from BII |
2020-12-02 |
| Slack Technologies–Salesforce: investment, 202012– acquisition $27.7b in cash + shares of Slack by Salesforce ANNOUNCED |
2020-12-01 |
| SynOx Therapeutics–Odlander Fredrikson: investment, 202011 financing round Series A totalling €37m incl co-lead investor HealthCap |
2020-11-19 |
| SynOx Therapeutics–SEVERAL: investment, 202011 financing round Series A €37m co-led by HealthCap + Medicxi with Forbion + Gimv |
2020-11-19 |
| BioInvent–Van Herk: investment, 202011 existent Van Herk is largest shareholder of BioInvent |
2020-11-18 |
| DCprime–Immunicum: investment, 202011– merger with former Immunicum shareholders holding 56% + Van Herk holding 43% of combined company ANNOUNCED |
2020-11-18 |
| Synendos Therapeutics–SEVERAL: investment, 202011 financing round Series A CHF20m co-led by Kurma Partners + Sunstone LSV |
2020-11-12 |
| Emisphere–Novo Group: investment, 202011– acquisition of Emisphere by Novo Nordisk for $1.35b in cash on a cash/debt-free basis |
2020-11-06 |
| The Protein Brewery–SEVERAL: investment, 202011 financing round Series A €22m led by Novo Holdings |
2020-11-03 |
| Monocl–Definitive Healthcare: investment, 202010 acquisition of Monocl by Definitive Healthcare LLC |
2020-10-29 |
| Galecto–LifeSci: public relations, 202010 supply service existent media contact LifeSci Advisors |
2020-10-28 |
| Galecto–SEVERAL: investment, 202010 US IPO $85m+12.75m with 5.67m+850k common stock shares at $15/share |
2020-10-28 |
| Kaffe Bueno–Denmark (govt): investment, 202010 seed financing round totalling €1.1m incl investor Vaekstfonden |
2020-10-27 |
| Kaffe Bueno–OTHER: investment, 202010 seed financing round totalling €1.1m incl a Danish business angel as investor |
2020-10-27 |
| Kaffe Bueno–Paulig Group: investment, 202010 seed financing round totalling €1.1m incl investor PINC |
2020-10-27 |
| Kaffe Bueno–SEVERAL: investment, 202010 seed financing round €1.1m from PINC + Vaekstfonden + The Yield Lab + a Danish business angel |
2020-10-27 |
| Kaffe Bueno–Yield Lab: investment, 202010 seed financing round totalling €1.1m incl investor The Yield Lab IE |
2020-10-27 |
| Prokarium–Flerie Invest: investment, 202010 financing round Series B totalling $21m incl co-investor Flerie Invest (FF) |
2020-10-27 |
| Prokarium–SEVERAL: investment, 202010 financing round Series B $21m led by Korea Investment Partners |
2020-10-27 |
| VectivBio–SEVERAL: investment, 202010 crossover financing $110m from existing + new investors |
2020-10-15 |
| Oncopeptides–EU (govt): credit, 202010– unsecured €40m loan facility in three tranches with each 5y maturity from EIB |
2020-10-14 |
| Rappta Therapeutics–Advent Venture Partners: investment, 202010 financing round Series A totalling €9m incl co-investor Advent Life Sciences |
2020-10-13 |
| Rappta Therapeutics–Novartis: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novartis Venture Fund |
2020-10-13 |
| Rappta Therapeutics–Novo Group: investment, 202010 financing round Series A totalling €9m incl co-lead investor Novo Seeds |
2020-10-13 |
| Rappta Therapeutics–Optimum Strategic Communications: public relations, 202010 service existent by Optimum |
2020-10-13 |
| Rappta Therapeutics–OTHER: investment, 202010 financing round Series A totalling €9m incl a family office as co-investor |
2020-10-13 |
| Rappta Therapeutics–SEVERAL: investment, 202010 financing round Series A €9m co-led by NVF + Novo Seeds |
2020-10-13 |
| Priothera–Odlander Fredrikson: investment, 202010 financing round Series A totalling €30m incl co-lead investor HealthCap |
2020-10-12 |
| Priothera–SEVERAL: investment, 202010 financing round Series A €30m led by Fountain Healthcare Partners |
2020-10-12 |
| Rare Thyroid Therapeutics–PledPharma: investment, 202010–202011 acquisition of RTT for SEK60m + 63.77m new shares + milestones |
2020-10-05 |
| Galecto–SEVERAL: investment, 202009 financing round $64m led by Soleus + co-lead by Eir Ventures |
2020-09-25 |
| Jennewein Biotechnologie–Chr. Hansen: investment, 202009– acquisition €310m on debt-free basis ANNOUNCED |
2020-09-22 |
| Sundew–Novo Group: investment, 202009 seed financing round totalling €1.4m inkl DKK10m (€1.34m) from Novo Nordisk BII |
2020-09-22 |
| Sundew–SEVERAL: investment, 202009 seed financing round €1.4m with €1.34m from Novo Nordisk BII + €85k from StartLife |
2020-09-22 |
| Sundew–StartLife (NL): investment, 202009 seed financing round totalling €1.4m inkl €85k from StartLife |
2020-09-22 |
| Lava Therapeutics–Novo Group: investment, 202009 financing round Series C totalling $83m incl new + co-lead investor Novo Ventures |
2020-09-17 |
| Lava Therapeutics–SEVERAL: investment, 202009 financing round Series C $83m co-led by Novo Ventures + Sanofi Ventures |
2020-09-17 |
| Umotif–SEVERAL: investment, 202009 financing round Series A £5m led by existing investor AlbionVC |
2020-09-03 |
| Cartana–10x Genomics: investment, 202008 acquisition of Cartana AB by 10x Genomics Inc |
2020-08-31 |
| Scienion–Cellink: investment, 202008– acquisition €80m on cash/debt-free basis with €40m in shares + €40m in shares |
2020-08-19 |
| Genkyotex–Calliditas Therapeutics: investment, 202008– acquisition in two steps for €32.3m in cash + €55m milestones (contingent rights) ANNOUNCED |
2020-08-13 |
| F2G Ltd–Novo Group: investment, 202008 financing round totalling $60.8m incl exisiting investor Novo Ventures |
2020-08-12 |
| F2G Ltd–SEVERAL: investment, 202008 financing round $60.8m from new investor Cowen Healthcare Investments + existing investors |
2020-08-12 |
| Oasmia–Consilium: public relations, 202008 service existent by CSC |
2020-08-10 |
| Reapplix–Denmark (govt): investment, 202007 financing round totalling DKK150m ($22.6m) incl existing investor Vaekstfonden |
2020-07-14 |
![[LSS] Life-Sciences-Scandinavia.com - The Scandinavian Life Sciences Web Portal](/images/basics/lss-life-sciences-scandinavia-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] Back into Ad 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-back-into-ad.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
